Medizinische Universität Graz - Research portal
Selected Publication:
Fruhwald, FM; Eber, B; Rotman, B; Toplak, H; Klein, W.
Silent myocardial ischemia. Current concepts of prognosis and therapy
ACTA MED AUST. 1991; 18(4): 90-92.
Web of Science
PubMed
- Leading authors Med Uni Graz
- Fruhwald Friedrich
- Co-authors Med Uni Graz
- Rotman Brigitte
- Toplak Hermann
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Type-I-patients with silent myocardial ischemia (SMI) have a 2-4fold higher longterm-risk for coronary-events than healthy people. With increasing gravity and duration of ischemia type-II-patients have an increased event-risk. Reliable statements about prognosis of type-III-patients are very difficult. Therapy of SMI is equivalent to therapy of "loud" ischemia and comprises: 1) treatment of cardiovascular risk-factors (nicotine, arterial hypertension, hyperlipidemia, adiposis), 2) nitrates as effective straight at the coronary stenosis, 3) beta-blockers, which influence the circadian ischemic rhythm, 4) calcium-channel-blockers with especially for nifedipine little effect, 5) thrombocyte-aggregation inhibitors and 6) invasive therapeutical methods (percutaneous transluminal coronary angioplasty [PTCA] and aorto-coronary bypass grafting [ACBG]).
- Find related publications in this database (using NLM MeSH Indexing)
- Angina Pectoris - mortality
- Combined Modality Therapy - mortality
- Coronary Disease - mortality
- Humans - mortality
- Myocardial Infarction - mortality
- Prognosis - mortality
- Risk Factors - mortality
- Find related publications in this database (Keywords)
- Coronary Heart Disease
- Silent Myocardial Ischemia
- Acute Myocardial Infarction
- Smi-Prognosis
- Smi-Therapy